List of Iheezo drug patents
Iheezo is owned by Sintetica Sa.
Iheezo contains Chloroprocaine Hydrochloride.
Iheezo has a total of 1 drug patent out of which 0 drug patents have expired.
Iheezo was authorised for market use on 27 September, 2022.
Iheezo is available in gel;ophthalmic dosage forms.
Iheezo can be used as method of inducing ocular anesthesia.
The generics of Iheezo are possible to be released after 15 September, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792271 | SINTETICA SA | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 27, 2025 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
Dosage: GEL;OPHTHALMIC
IHEEZO family patents
3
United States
1
Israel
1
South Africa
1
IB
1
Australia
1
Jordan
1
Morocco
1
Philippines
1
Costa Rica
1
Cuba
1
Singapore
1
Colombia
1
Brazil
1
Korea, Republic of
1
Peru
1
Chile
1
China
1
Ecuador
1
Japan
1
EA
1
Canada
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic